Skip to main content
SpringerLink
Log in

Management of aggressive pituitary adenomas: current treatment strategies

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Aggressive pituitary adenomas are notoriously difficult to manage due to their size, invasiveness, speed of growth and high frequency of recurrence. Except for prolactinomas, surgery (usually transsphenoidal but sometimes transcranial) is the first-line option, but re-growth of aggressive tumors is almost inevitable and monitoring and repeat surgery is required to control symptoms. In prolactinomas, dopamine agonists are the first-line treatment and they normalize prolactin levels in most patients even with macroprolactinomas. Somatostatin analogues offer another pharmacotherapy for pituitary adenomas either for primary therapy, pre-operatively to reduce the tumor volume and make it more amenable to surgical removal, or post-surgery to control re-expansion. When surgery and pharmacotherapy fail, radiotherapy is a useful third-line strategy that reduces recurrence, while extreme pituitary adenomas with metastases may potentially be managed with chemotherapy (although more data are needed). A combination of these therapies will be required for aggressive pituitary adenomas and careful follow-up is essential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Schloffer H (1907) Erfolgreiche Operation eines Hypophysentumors auf nasalem Wege. Wien Klin Wochenschr 20:621–624

    Google Scholar 

  2. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534. doi:10.1210/er.2005-9998

    Article  PubMed  CAS  Google Scholar 

  3. Biller BM, Molitch ME, Vance ML et al (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81(6):2338–2343. doi:10.1210/jc.81.6.2338

    Article  PubMed  CAS  Google Scholar 

  4. Colao A, Di Sarno A, Landi ML et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579. doi:10.1210/jc.82.11.3574

    Article  PubMed  CAS  Google Scholar 

  5. Colao A, Di Sarno A, Landi ML et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247–2252. doi:10.1210/jc.85.6.2247

    Article  PubMed  CAS  Google Scholar 

  6. Ferrari CI, Abs R, Bevan JS et al (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 46(4):409–413. doi:10.1046/j.1365-2265.1997.1300952.x

    Article  CAS  Google Scholar 

  7. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331(14):904–909. doi:10.1056/NEJM199410063311403

    Article  PubMed  CAS  Google Scholar 

  8. Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84(7):2518–2522. doi:10.1210/jc.84.7.2518

    Article  PubMed  CAS  Google Scholar 

  9. Zatelli MC, Ambrosio MR, Bondanelli M, Uberti EC (2007) Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur J Endocrinol 156(suppl 1):S29–S35. doi:10.1530/eje.1.02352

    Article  PubMed  CAS  Google Scholar 

  10. Vance ML, Laws ER Jr (2005) Role of medical therapy in the management of acromegaly. Neurosurgery 56(5):877–885. discussion-85

    PubMed  Google Scholar 

  11. Caron P, Bex M, Cullen DR et al (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60(6):734–740. doi:10.1111/j.1365-2265.2004.02045.x

    Article  CAS  Google Scholar 

  12. Maiza JC, Vezzosi D, Matta M et al (2007) Long-term (upto 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67(2):282–289. doi:10.1111/j.1365-2265.2007.02878.x

    Article  CAS  Google Scholar 

  13. Mercado M, Borges F, Bouterfa H et al (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859–868. doi:10.1111/j.1365-2265.2007.02825.x

    Article  CAS  Google Scholar 

  14. Karavitaki N, Turner HE, Adams CB et al (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68(6):970–975. doi:10.1111/j.1365-2265.2007.03139.x

    Article  CAS  Google Scholar 

  15. Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856–1863. doi:10.1210/jc.2004-1093

    Article  PubMed  CAS  Google Scholar 

  16. Colao A, Marzullo P, Ferone D et al (1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22(1):40–47

    PubMed  CAS  Google Scholar 

  17. Cozzi R, Barausse M, Sberna M et al (2000) Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary 3(4):231–238. doi:10.1023/A:1012832230598

    Article  PubMed  CAS  Google Scholar 

  18. Colao A, Pivonello R, Auriemma RS et al (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91(6):2112–2118. doi:10.1210/jc.2005-2110

    Article  PubMed  CAS  Google Scholar 

  19. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M (2007) Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60(6):993–1002 discussion 3-4

    Article  PubMed  Google Scholar 

  20. Fadul CE, Kominsky AL, Meyer LP et al (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105(4):621–626. doi:10.3171/jns.2006.105.4.621

    Article  PubMed  Google Scholar 

  21. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7(6):518–520. doi:10.1016/S1470-2045(06)70728-8

    Article  PubMed  Google Scholar 

  22. Syro LV, Uribe H, Penagos LC et al (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65(4):552–553. doi:10.1111/j.1365-2265.2006.02653.x

    Article  Google Scholar 

  23. Kovacs K, Horvath E, Syro LV et al (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38(1):185–189. doi:10.1016/j.humpath.2006.07.014

    Article  PubMed  CAS  Google Scholar 

  24. Neff LM, Weil M, Cole A et al (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81–86. doi:10.1007/s11102-007-0014-1

    Article  PubMed  Google Scholar 

  25. Kovacs K, Scheithauer BW, Lombardero M et al (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115(2):261–262. doi:10.1007/s00401-007-0279-5

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University of Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany

    Michael Buchfelder

Authors
  1. Michael Buchfelder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Buchfelder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buchfelder, M. Management of aggressive pituitary adenomas: current treatment strategies. Pituitary 12, 256–260 (2009). https://doi.org/10.1007/s11102-008-0153-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-008-0153-z

Keywords

Search

Navigation